Summary:
- This article discusses a new diagnostic test called DecisionDx-Melanoma, developed by Castle Biosciences, a company that specializes in genomic testing for cancer.
- The test analyzes the genetic profile of a patient's melanoma tumor to determine the risk of the cancer spreading or metastasizing, which can help guide treatment decisions.
- Early detection and appropriate treatment are crucial for improving outcomes in melanoma, and this new test provides valuable information to healthcare providers and patients to make more informed decisions about their care.